



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	☒ HIV-1 IIIB A17 Variant Virus
<b>Catalog Number:</b>	1413
<b>Lot Number:</b>	120132
<b>Release Category:</b>	A
<b>Provided:</b>	1 ml cell-free viral supernatant obtained from persistently infected H9 cells. The culture medium contains 90% RPMI 1640, 10% fetal bovine serum, penicillin and streptomycin.
<b>Original Source:</b>	Derived by passage of HIV-1 IIIB in H9 cells (human T-lymphoid) in the presence of increasing concentrations of a pyridinone RT non-nucleoside inhibitor.
<b>Sterility:</b>	Negative for bacteria, mycoplasma, and fungi.
<b>Description:</b>	R5 and X4.
<b>Special Characteristics:</b>	The A17 variant is highly resistant to inhibition by RT nonnucleoside inhibitors, including pyridinone derivatives, BI-RG-587, and TIBO compounds. Resistance results from mutations at amino acids 103 (K→N) and 181 (Y→C) in the viral RT domain. Use the entire aliquot provided to infect $1 \times 10^6$ H9 cells. Host of Choice: H9 or MT-4 cells. Titer: $7.41 \times 10^6$ TCID <sub>50</sub> /ml, titrated in H9 cells. p24 ng/mL is >1,782
<b>Recommended Storage:</b>	Liquid nitrogen.
<b>Contributor:</b>	Dr. Emilio Emini.
<b>References:</b>	Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman AM, Emini EA, Goldman ME. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. <i>J Virol</i> <b>65</b> :4887-4892, 1991.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, AIDS Program, NIAID, NIH: HIV-1<sub>IIIB</sub> (A17 Variant) from Dr. Emilio Emini." Also include the reference cited above in any publications.

**Last Updated:**

July 06, 2018

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.